Immunophotonics and Swiss Cancer Institute Complete SAKK 66/17 Phase 1b/2a Multicenter Clinical Trial for Treatment of Solid Tumors

ST. LOUIS, Aug. 21, 2025 /PRNewswire/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel immune-stimulating drugs to augment routine tumor destruction techniques, announced the completion of its multicenter clinical trial (SAKK 66/17) conducted in...